Table 2
Selected adverse events considered to be IFN-related
| Preferred term | IFN beta-1a (%) | Placebo (%) | p value |
|---|---|---|---|
| *Percentages represent patients reporting adverse event at least once. | |||
| †Includes patients with elevated alanine transaminase, elevated aspartate transaminase, or abnormal hepatic function. | |||
| IFN, interferon (Rebif®, 22 μg once weekly). | |||
| Flu like symptoms | 37* | 22 | 0.002 |
| Headache | 36 | 20 | 0.002 |
| Injection site inflammation | 31 | 4 | <0.001 |
| Injection site reaction | 27 | 8 | <0.001 |
| Depression | 20 | 14 | 0.128 |
| Fatigue | 19 | 13 | 0.117 |
| Myalgia | 15 | 8 | 0.048 |
| Fever | 10 | 4 | 0.024 |
| Elevation of liver enzymes† | 3 | 0 | 0.061 |
| Lymphopenia | 1 | 2 | 0.362 |
